Online inquiry

IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6367MR)

This product GTTS-WQ6367MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6367MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4069MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ7599MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ2501MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ3824MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ14656MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ14433MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ14463MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ10771MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW